Ozmosi | Anacetrapib Drug Profile

Product Description

Anacetrapib is a potent inhibitor of CETP that increases circulating levels of high-density lipoprotein (HDL) cholesterol and lowers the levels of non-HDL cholesterol [particularly low-density lipoprotein (LDL) cholesterol]. (Sourced from: https://doi.org/10.1093/eurheartj/ehab863)

Mechanisms of Action: CETP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Hyperlipoproteinemia Type V|Hypercholesterolemia|Hyperlipidemia|Dyslipidemia

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
2011-004525-27	Study of Anaceptrapib in Heterozygous Familial Hypercholesterolemia	P3	Completed	Hypercholesterolemia	2018-11-13	35%	2022-03-13	Treatments
NCT02931188	REVEAL-Vasc	N/A	Completed	Atherosclerosis	2018-05-01		2019-03-21	Treatments
NCT01252953	REVEAL	P3	Active, not recruiting	Atherosclerosis	2017-01-31	35%	2022-05-04	Primary Endpoints
2010-023467-18	REVEAL Version 1.0	P3	Unknown status	Myocardial Infarction\|Coronary Disease	2016-09-25	35%	2025-07-04	Treatments
CTR20130983	CTR20130983	N/A	Completed	Hypercholesterolemia	2016-08-24		2025-04-29	Patient Enrollment\|Treatments
CTR20130982	CTR20130982	P3	Completed	Hypercholesterolemia	2015-08-20		2025-04-29	Patient Enrollment
NCT01860729	MK-0859-022	P3	Completed	Hypercholesterolemia	2015-05-29		2022-05-04	Primary Endpoints\|Treatments
NCT01760460	MK-0859-051 AM1	P3	Completed	Dyslipidemia	2015-03-04		2022-05-04	Primary Endpoints\|Treatments
JapicCTI-132236	JapicCTI-132236	P3	Completed	Dyslipidemia	2015-03-01
NCT01717300	MK-0859-021	P3	Completed	Hypercholesterolemia	2014-10-29		2022-05-04	Primary Endpoints\|Treatments
2012-003110-14	2012-003110-14	P3	Completed	Hypercholesterolemia	2014-10-29		2022-03-13	Treatments
NCT01841684	MK-0859-042	P3	Terminated	Hyperlipoproteinemias\|Hypercholesterolemia\|Hyperlipidemia\|Hyperlipoproteinemia Type II	2014-06-01		2022-05-04	Primary Endpoints
JapicCTI-132234	JapicCTI-132234	P3	Completed	Hypercholesterolemia	2014-05-01
NCT01824238	MK-0859-050	P3	Completed	Hyperlipoproteinemia Type II\|Hypercholesterolemia	2014-05-01		2022-05-04	Primary Endpoints\|Treatments
NCT01524289	REALIZE	P3	Completed	Hyperlipoproteinemia Type II\|Hyperlipoproteinemias\|Hypercholesterolemia\|Hyperlipidemia	2014-02-12	35%	2022-05-04
2012-002434-37	Anacetrapib in Patients with Homozygous Familial Hypercholesterolemia	P3	Terminated	Hypercholesterolemia	2014-02-04		2022-03-13	Treatments
2007-005839-28	Efficacy of Anacetrapib withStatin	P3	Completed	Coronary Disease	2012-12-03		2022-03-12	Treatments
NCT00990808	0859-026 AM3	P1	Completed	Dyslipidemia	2011-06-01		2022-05-04	Primary Endpoints\|Treatments
NCT01122667	MK-0859-038	P1	Completed	Dyslipidemia\|Kidney Diseases	2011-06-01		2022-05-04	Primary Endpoints\|Treatments
NCT01114490	MK-0859-039	P1	Completed	Hepatic Insufficiency\|Dyslipidemia\|Liver Failure	2010-07-01		2022-05-04	Primary Endpoints
NCT00977288	NCT00977288	P2	Completed	Dyslipidemia	2010-03-01		2022-05-04	Primary Endpoints\|Treatments
NCT00685776	DEFINE	P3	Completed	Coronary Artery Disease\|Myocardial Ischemia	2009-07-02		2022-05-04	Primary Endpoints
NCT00325455	NCT00325455	P2	Terminated	Hyperlipidemia\|Hypercholesterolemia\|Hyperlipoproteinemia Type V	2007-02-01		2022-05-04	Primary Endpoints\|Treatments
NCT00565006	NCT00565006	P1	Completed	Other	2006-09-01		2025-08-27	Treatments
NCT00565292	NCT00565292	P1	Completed	Hyperlipidemia\|Hyperlipoproteinemias\|Hypercholesterolemia	2006-08-01		2022-05-04	Treatments

Recent News Events

Date	Type	Title
04/22/2024	PubMed	CETP inhibition enhances monocyte activation and bacterial clearance and reduces streptococcus pneumonia-associated mortality in mice.
11/01/2023	PubMed	The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease.
10/03/2023	PubMed	Impact of New Cardiovascular Events on Quality of Life and Hospital Costs in People With Cardiovascular Disease in the United Kingdom and United States.
08/11/2022	News Article	NewAmsterdam Pharma Announces Publication in Nature Medicine Discussing Clinical Potential of Obicetrapib
02/14/2022	News Article	New Review Article in ESC's Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) Inhibition's Role in Reducing Cardiovascular Disease Risk
01/14/2021	News Article	NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program
08/20/2019	News Article	Cardiovascular Drugs Market to be worth US$ 91.0 Billion by 2025, Says TMR

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Anacetrapib

Alternative Names: anacetrapib, mk0859, mk-0859, mk 0859 Clinical Status: Inactive Latest Update: 2024-04-22 Latest Update Note: PubMed Publication